Drug intelligence / Profile preview

LW-1017

Development stage: Unknown
Lead developer: Lysoway Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

LW-1017 is a brain-penetrant small-molecule agonist of the lysosomal calcium channel TRPML1 (Mucolipin-1), developed by Lysoway Therapeutics for the treatment of age-related neurodegenerative disorders. By activating TRPML1, the drug aims to restore the function of the autophagy-lysosomal pathway, which is often impaired in diseases like Parkinson's and Alzheimer's. Preclinical data indicates that LW-1017 effectively crosses the blood-brain barrier, reduces the accumulation of alpha-synuclein, amyloid-beta, and phosphorylated tau, and provides neuroprotection. The candidate has completed IND-enabling studies and is scheduled for first-in-human Phase I clinical trials in May 2026.

Targets

MCOLN1 (Transient receptor potential cation channel mucolipin subfamily member 1)

Beyond the preview

Go deeper on LW-1017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LW-1017.

Explore the full profile